Skip to content
Screener

Rapport Therapeutics, Inc. RAPP Other operating expenses

Other operating expenses at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$123.16M+30.7%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$96.9M+27.4%
Septerna, Inc. logo
Septerna, Inc.SEPN
$43.58M+49.8%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$23.62M+5.0%
CalAmp logo
CalAmpCAMP
$14.37M+2.9%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$2.61M+12.6%

Other financials

Income statement

See full
Revenue-
Operating income-$60.8M-106%
Net income-$56.6M-112%
EPS (diluted)-$1.19-58.7%

Balance sheet

See full
Cash & equivalents$63.6M+15.5%
Total debt$10.1M-14.8%
Total equity$422.9M+60.5%
Total assets$459.0M+60.8%

Cash flow

See full
Operating cash flow-$41.5M-65.4%
CapEx$78.0K+255%
Free cash flow-$41.5M-65.5%

Valuation

See full
Market cap$2.22B+317%
Enterprise value$2.17B+343%
P/S111.2×

Profitability

See full
Operating margin-767.6%
Net margin-685.8%
FCF margin-485.7%

Returns & leverage

See full
Return on equity-40%+22.3pp
Debt / equity0.0×
Current ratio15.7×-7.0×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:30 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333862
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For The Six Months Ended June 30, 2026For The Six Months Ended June 30, 2025
Operating expenses
Research and development51,41422,68084,13042,252
Selling, general and administrative9,3926,81620,89114,352
Total operating expenses60,80629,496105,02156,604
Loss from operations(60,806)(29,496)(85,021)(56,604)
Other income:
Interest income4,1912,7648,5495,809
Total other income4,1912,7648,5495,809

Item 1. Financial Statements.

FAQ

What is Rapport Therapeutics, Inc.'s other operating expenses?
Rapport Therapeutics, Inc. (RAPP) reported other operating expenses of $60.81M in Q2 2026.
How has Rapport Therapeutics, Inc.'s other operating expenses changed year-over-year?
Rapport Therapeutics, Inc.'s other operating expenses increased by 106.1% year-over-year, from $29.5M to $60.81M.
What is the long-term trend for Rapport Therapeutics, Inc.'s other operating expenses?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s other operating expenses has grown at a 86.0% compound annual growth rate (CAGR), from $36.18M to $125.1M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.

Ask your AI about Rapport Therapeutics, Inc.'s other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude